75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Acquisition of ZebiAI link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stock Compensation link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Long-Lived Assets link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Acquisition of ZebiAI (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Stock Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Long-Lived Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Segment Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Segment Information - Schedule of Reportable Segment Revenue, Operating Expenses, and Net Loss (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Contingent Consideration Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Investments - Available-for-sale Debt Securities in an Unrealized Loss Position (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Investments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Acquisition of ZebiAI - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Acquisition of ZebiAI - Summary of Net Assets Acquired Based on Estimated Fair Values (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Common Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Stock Compensation - Schedule of Stock Compensation Expense in the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Collaboration and License Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Long-Lived Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Long-Lived Assets - Summary of Adjustments and Reconciliation to Net Amount (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Long-Lived Assets - Schedule of Operating Leases Presentation in Condensed Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Long-Lived Assets - Summary of Operating Lease Presentation in Condensed Consolidated Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Long-Lived Assets - Summary of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Long-Lived Assets - Summary of Future Minimum Lease Payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink Acquisition-related costs Business Combination, Acquisition-Related Cost, Expense Other Research and Development Expense Other expenses Proceeds from Sale and Maturity of Other Investments, Total Proceeds from Sale and Maturity of Other Investments Proceeds from maturities and sales of investments One Kendall Square, Cambridge, MA. 300 OKS [Member] 300 One Kendall Square Cambridge MA Member Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Preferred Stock, Shares Issued, Total Preferred stock shares issued Preferred Stock, Shares Issued Research and Development Expense [Abstract] Research and development expenses 12 Months or Longer, Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Entity Current Reporting Status Entity Current Reporting Status U.S agency securities [Member] US Government Agencies Debt Securities [Member] U.S. agency securities [Member] Operating expenses: Operating Expenses [Abstract] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common stock shares authorized Common Stock, Shares Authorized Amount receivable upon achievement of regulatory and commercial milestones Amount Receivable Upon Achievement Of Regulatory And Commercial Milestones Amount receivable upon achievement of regulatory and commercial milestones. Product and Service Product and Service [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Entity Shell Company Entity Shell Company Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalent Cowen [Member] Cowen [Member] Cowen. Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Common Stock, Shares, Issued, Total Common stock shares issued Common Stock, Shares, Issued Summary Of Operating Lease Presentation In Consolidated Statements Of Operations And Comprehensive Loss Table [Text Block] Summary of operating lease presentation in consolidated statements of operations and comprehensive loss. Summary of Operating Lease Presentation in Condensed Consolidated Statements of Operations Asset Class Asset Class [Domain] Statement [Table] Statement [Table] Restricted cash Restricted Cash, Noncurrent Operating lease assets obtained in exchange for operating lease liabilities Right-of-Use Assets Obtained in Exchange for Operating Lease Liabilities Area Of Office And Laboratory Space Under Operating Lease Terminated Area of office and laboratory space under operating lease terminated Area of office and laboratory space under operating lease terminated. Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Statement [Line Items] Statement [Line Items] TD securities. T D Securities [Member] TD Securities [Member] Business Acquisition, Acquiree Business Combination [Domain] Entity Filer Category Entity Filer Category Milestone payments Milestone Payments Milestone payments. Liabilities and Equity Total liabilities and stockholders' equity Commitments And Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Table] Commitments and contingencies disclosure. Industry Sector [Axis] Schedule Of Operating Lease Presentation In Consolidated Balance Sheet Table [Text Block] Schedule of operating lease presentation in consolidated balance sheet. Schedule of Operating Leases Presentation in Condensed Consolidated Balance Sheets Periodic change in additions of property and equipment within current liabilities Periodic Change in Additions of Property And Equipment Within Current Liabilities Periodic change in additions of property and equipment within current liabilities. Cash and Cash Equivalents, Fair Value Disclosure Assets, fair value Options outstanding to purchase common stock [Member] Geographical [Domain] Periodic Change in Costs to Obtain License Agreement Within Current Liabilities Periodic change in costs to obtain license agreement within current liabilities. Periodic change in costs to obtain license agreement within current liabilities Change in fair value of contingent consideration liability Amount of increase (decrease) in the fair value of contingent consideration recognized in the income statement. Change in fair value of contingent consideration liability Investments with a maturity of one year or less [Member] Investments With Maturity Of One Year Or Less [Member] Investments with maturity of one year or less. Payment for Relocation under Lease Agreement Payment for relocation under lease agreement. Relocation Payment Significant Accounting Policies Significant Accounting Policies [Text Block] Property, Plant and Equipment [Line Items] Summary of Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Net loss per share, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Net loss per share, basic Summary of Fair Value of Available-for-Sale Investments by Type of Security Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Addition to Operating Lease Asset Upon Commencement of New Lease Addition to operating lease asset upon commencement of new lease. Carryover to 300 OKS Total current liabilities Liabilities, Current Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract] Reconciliation to consolidated net loss: Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Contingent consideration payment description Business Combination, Contingent Consideration, Description Consolidation Items [Domain] Payment For Upfront Consideration Payment for upfront consideration. Payment for upfront consideration Equity, Attributable to Parent [Abstract] Stockholders' equity: Entity Small Business Entity Small Business Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Industry Sector [Domain] Number Of New Genetic Disease Programs Number of new genetic disease programs. Number of genetic disease programs Weighted average sales price per shares. Weighted-average sales price per share Weighted-Average Sales Price per Share Offering price per share Shares issue price per share Sale of Stock, Price Per Share Long Lived Assets [Text Block] Long lived assets. Long-Lived Assets Stock Compensation Share-Based Payment Arrangement [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Genetic Disease Portfolio [Member] Genetic Disease Portfolio [Member] Genetic disease portfolio. Leases [Abstract] Amendment Flag Amendment Flag OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Unrealized holding (loss) gain Product and Service Product and Service [Domain] Schedule of Held-to-maturity Securities [Line Items] Schedule of Held-to-Maturity Securities [Line Items] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Segment reporting, CODM, profit (loss) measure, how used, description Common Stock [Member] Common Stock [Member] Investments with a maturity of one to two years [Member] Investments With Maturity Of One To Two Years [Member] Investments with maturity of one to two years. Lessee, Operating Lease, Liability, to be Paid, Year Three 2028 Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Entity Address Address Line1 Entity Address, Address Line One Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Earnings Per Share [Abstract] Supplemental disclosure of non-cash activities: Supplemental Cash Flow Information [Abstract] Receivable from transfer of active pharmaceutical ingredient Receivable from transfer of active pharmaceutical ingredient. Amount receivable from transfer of active pharmaceutical ingredient and other materials Right of use asset Operating lease assets Operating Lease, Right-of-Use Asset Total, Fair Value Total, Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position Document Type Document Type Business Combination Contingent Consideration Liabilities Contingent Milestone Payments Business combination contingent consideration liabilities contingent milestone payments. Business combination contingent consideration liabilities contingent milestone payments Issuance of common stock upon milestone achievement, shares. Issuance of common stock upon milestone achievement, shares Entity Central Index Key Entity Central Index Key Investments, Debt and Equity Securities [Abstract] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase (decrease) in cash, cash equivalents, and restricted cash Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Operating lease assets and liabilities, net Operating lease assets and liabilities, net Increase decrease in operating lease assets and liabilities net Increase decrease in operating lease assets and liabilities net. Directors and Officers [Member] Directors and Officers. Common stock par value Common Stock, Par or Stated Value Per Share DE Shaw Research [Member] D E Shaw Research [Member] DE shaw research. Collaborative Arrangement, Nature and Purpose Collaborative arrangement, purpose Other liabilities Increase (Decrease) in Other Operating Liabilities Increase (Decrease) in Other Operating Liabilities, Total Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Debt Securities, Available-for-sale, Total Fair Value Debt Securities, Available-for-Sale Issuance of common stock through/upon exercise of stock options, shares Issuance of common stock in follow-on offering, net, shares Issuance of common stock through exercise of stock options, shares Follow on offering. Follow-on Offering [Member] Follow-On Offering [Member] Follow-On Offering [Member] Elevar Therapeutics, Inc [Member] Elevar Therapeutics, Inc. Elevar [Member] Investments Investments [Text Block] Accrued Liabilities, Current, Total Accrued expenses Accrued expenses and other current liabilities Accrued Liabilities, Current Current Fiscal Year End Date Current Fiscal Year End Date Document Quarterly Report Document Quarterly Report Entity Address, State or Province Entity Address, State or Province Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock shares outstanding Preferred Stock, Shares Outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Rule 10b5-1 Arrangement Modified Rule 10b 5 Arr Modified Flag Rule 10b5 Arr Modified Flag. Number of New Novel Programs Number of New Novel Programs Number of novel programs Geographical [Axis] Issuance of common stock through/upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock through exercise of stock options Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive (loss) income: Schedule of changes in fair value of contingent consideration liability. Schedule Of Changes In Fair Value Of Contingent Consideration Liability [Table Text Block] Schedule of Changes in Contingent Consideration Liability License agreement transaction price License Agreement Transaction Price License agreement aransaction price. ZebiAI Therapeutics, Inc. [Member] Zebi A I Therapeutics Inc [Member] ZebiAI Therapeutics, Inc. Property, Plant and Equipment [Abstract] Antidilutive Securities Antidilutive Securities [Axis] Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Stock Compensation Expense in the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss Related Party Transaction Related Party Transaction [Axis] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive (Loss)/ Income [Member] Two thousand twenty four sales agreement. Two Thousand Twenty Four Sales Agreement [Member] 2024 Sales Agreement [Member] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Business Combination, Consideration Transferred, Total Consideration transferred Business Combination, Consideration Transferred Recently Issued Accounting Pronouncements Not Yet Adopted Description Of New Accounting Pronouncements Not Yet Adopted Policy [Text Block] Description of new accounting pronouncements not yet adopted. Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 Intangible asset Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived Minimum [Member] Minimum [Member] Financial Instrument Financial Instrument [Axis] At-the-Market Offerings. At-the-Market Offerings [Member] At-the-Market Offering Current assets: Assets, Current [Abstract] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Number of novel programs Number of Novel Programs Number of novel programs. Segment Reporting [Abstract] Business Combination, Recognized Asset Acquired, Asset Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total Assets obtained in asset acquisition Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Beginning balance, shares Ending balance, shares Shares, Outstanding Available-for-sale Debt Securities in an Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Commitments and contingencies (Note 9) Commitments and Contingencies General and Administrative Expense [Member] General and administrative expenses [Member] General and Administrative Expenses [Member] Operating Lease, Liability Total lease liabilities Present value of operating lease liabilities Total operating lease liabilities Total operating lease liabilities Proceeds from issuance of common stock through follow-on offering, net Proceeds from issuance of common stock through follow-on offering, net. Proceeds from issuance of common stock through follow-on offering, net Undesignated Preferred Stock [Member] Undesignated preferred stock. UndesignatedPreferredStock [Member] 399 Binney Street [Member] 399 Binney Street, Cambridge, Massachusetts. 399 Binney Street Cambridge MA [Member] Payment for Lease Termination Payment for lease termination. Termination Payment Revenue from Contract with Customer, Product and Service [Extensible List] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Lessee, Lease, Description [Table] Text Block [Abstract] Restricted cash and cash equivalents at carrying value abstract. Restricted Cash And Cash Equivalents At Carrying Value [Abstract] Restricted Cash And Cash Equivalents At Carrying Value [Abstract] Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Weighted average shares of common stock, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Operating Leased Assets [Table] 12 Months or Longer, Unrealized Losses 12 Months or Longer, Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Other Segment Expenses Abstract Other segment expenses. Other segment expenses (income) Subsequent Events Subsequent Events [Text Block] Stock compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Beginning balance Ending balance Equity, Attributable to Parent Total stockholders' equity Payments to Acquire Investments, Total Purchases of investments Payments to Acquire Investments Preferred stock par value Preferred Stock, Par or Stated Value Per Share Lessee, Operating Lease, Existence of Option to Extend [true false] Operating lease renewal option Statement of Stockholders' Equity [Abstract] Number of discovery stage programs. Number of discovery stage programs Number of discovery stage programs Common Stock [Abstract] Common Stock [Abstract] Issuance of common stock upon milestone achievement Issuance of common stock upon milestone achievement Issuance of common stock upon milestone achievement. Weighted average number of shares outstanding diluted. Weighted Average Number Of Shares Outstanding Diluted Weighted average shares of common stock, diluted Cash equivalents [Member] Cash Equivalents [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Investments: Investments, Fair Value Disclosure [Abstract] Entity Address, Address Line Two Fair Value Measurements Fair Value Disclosures [Text Block] Elevar Agreement [Member] Elevar agreement. Elevar Agreement [Member] Other current assets Cash equivalents: Cash And Cash Equivalents Fair Value Disclosure [Abstract] Cash and cash equivalents fair value disclosure. Acquisition date Business Combination, Effective Date of Acquisition Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Upfront consideration payable Upfront Consideration Payable Upfront consideration payable. Nature of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] ZebiAI [Member] ZebiAI [Member] ZebiAI. Operating lease agreement expiration date Lease Expiration Month And Year Lease expiration month and year. Entity Address, City or Town Entity Address, City or Town Business Combination, Contingent Consideration, Liability, Total Contingent consideration liability Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Change in fair value of Contingent Earnout Payments Vesting of restricted stock units, Shares. Vesting of restricted stock units, Shares Security Exchange Name Security Exchange Name Intangible asset Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance Indefinite-Lived Intangible Assets (Excluding Goodwill), Total Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total Unrealized gain on investments Collaboration And License Arrangement [Line Items] Collaboration And License Arrangement [Line Items] Collaboration and license arrangement. Counterparty Name Counterparty Name [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Stockholders' Equity Note [Abstract] Proceeds from issuance of common stock through Private Placement, net. Proceeds From Issuance Of Common Stock Through Private Placement Net Proceeds from issuance of common stock through Private Placement, net Cash, cash equivalents, and restricted cash per statements of cash flows Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Cash, cash equivalents and restricted cash at beginning of period Statistical Measurement Statistical Measurement [Domain] Business Combination, Description [Abstract] Total current assets Assets, Current Total share-based compensation expense Share-Based Payment Arrangement, Expense Share-based compensation expense Document Period End Date Document Period End Date Other income: Other Income and Expenses [Abstract] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Impairment of intangible asset Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Loss on disposal of property and equipment Loss on disposal of property and equipment Basis Of Presentation Policy [Text Block] Basis of presentation. Basis of Presentation Statement of Financial Position [Abstract] Restricted Stock Units (RSUs) [Member] Unvested restricted stock units [Member] Unvested and outstanding restricted stock units [Member] Lessee, Operating Lease, Existence of Option to Terminate [true false] Operating lease option to terminate Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Class of Stock Class of Stock [Axis] Debt securities unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Acquired In-Process Research and Development In Process Research and Development, Policy [Policy Text Block] Total liabilities Liabilities Financial Instruments Financial Instruments [Domain] Deferred revenue Increase (Decrease) in Deferred Revenue Lessee, Operating Lease, Liability, to be Paid, Year Two 2027 Restricted Cash, Total Restricted cash Restricted Cash Unvested restricted stock [Member] Restricted Stock [Member] Less than 12 Months, Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Less than 12 Months, Unrealized Losses Weighted average shares of common stock, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Entity File Number Securities Act File Number Cover [Abstract] Other expense Other Expenses Other expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses U.S treasury bills [Member] US Treasury Securities [Member] U.S. treasury bills [Member] Business combination contingent consideration arrangements change in amount of contingent earnout payments Business combination contingent consideration arrangements change in amount of contingent earnout payments. Change in fair value of Contingent Earnout Payments Number of operating segments Number of Operating Segments Sale of Stock [Domain] Segment Information Segment Reporting Disclosure [Text Block] General and Administrative Expense, Total General and administrative expenses General and Administrative Expense Payment related to collaboration or other agreements Payment Related To Collaboration Or Other Agreements Payment related to collaboration or other agreements. Operating Leased Assets [Line Items] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Summary of Future Minimum Lease Payments Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Former Address [Member] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total Liabilities assumed in asset acquisition Business Combination, Recognized Liability Assumed, Liability Depreciation Depreciation, Total Depreciation expense Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock shares outstanding Common Stock, Shares, Outstanding Operating lease liabilities Operating Lease, Liability, Current Current operating lease liabilities Operating lease liabilities Document Transition Report Document Transition Report Total operating expenses Operating Expenses Collaboration agreement transaction price Collaboration Agreement Transaction Price Collaboration agreement transaction price. Research and Development Expense, Total Research and development expense Research and Development Expense Percentage of payment related to collaboration or other agreements Percentage Of Payment Related To Collaboration Or Other Agreements Percentage of payment related to collaboration or other agreements. Leases Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Schedule of Investments [Abstract] Statement of Cash Flows [Abstract] Adjustments And Reconciliation To Carryover Amount Of Lease [Table Text Block] Adjustments and reconciliation to carryover amount of lease. Adjustments and Reconciliation to Carryover Amount Stock Issued During Period, Value, New Issues Issuance of common stock via at-the-market offerings, net,value Common Stock Equity [Text Block] Common Stock Issued During Period Shares New Issues Common stock issued during period shares new issues. Common stock shares sold Earnings Per Share [Text Block] Net Loss Per Share Thereafter Lessee operating lease liability payments due after year four Lessee operating lease liability payments due after year four. Proceeds from issuance of common stock upon exercise of stock options. Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Proceeds from issuance of common stock through exercise of stock options Aggregate gross proceeds from the sale of shares Sale of Stock, Consideration Received Per Transaction Net loss Net loss Payment For Transfer Of Active Pharmaceutical Ingredient Payment for transfer of active pharmaceutical ingredient. Payment for transfer active pharmaceutical ingredient and other material Operating Lease, Cost Operating lease costs Operating Lease, Payments Fixed lease payments Assets Assets [Abstract] Proceeds from issuance of common stock via at the market offerings net. Proceeds From Issuance Of Common Stock Via At The Market Offerings Net Proceeds from issuance of common stock via at-the-market offerings, net Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Land subject to ground leases Operating lease executed Non Rule 10b51 Arr Modified Flag Non Rule 10b51 Arr Modified Flag. Non-Rule 10b5-1 Arrangement Modified Research and development expenses [Member] Research and Development Expense [Member] Research and Development Expense [Member] Weighted Average Sales Price Per Share1 Weighted average sales price per share. Weighted-average sales price per share Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Lessee, Operating Lease, Liability, to be Paid, Year One 2026 Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net acquired assets Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Schedule of compensation cost for share based payment arrangements allocation of share based compensation costs. Schedule of compensation cost for share based payment arrangements allocation of share based compensation costs [Table Text Block] Schedule of Stock Compensation Expense in Company's Condensed Consolidated Statements of Operations and Comprehensive Loss Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Sale of Stock [Axis] Total revenue Revenues Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by investing activities Private Placement [Member] Entity Addresses [Line Items] Commissions Paid Commissions paid. Commissions paid Title of 12(b) Security Title of 12(b) Security Schedule of Segment Reporting Information, by Segment [Table] Nature of Business and Basis of Presentation [Line Items] Nature Of Business And Basis Of Presentation [Line Items] Nature of business and basis of presentation. Money market funds [Member] Money Market Funds [Member] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2025 Document Information [Table] External Costs for Programs in Clinical Trials External costs for programs in clinical trials. External costs for programs in clinical trials Changes in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Average share value of 5-day Business Combination, Price Per Share Closing price of common stock Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Acquisition of ZebiAI Business Combination [Text Block] Additional Paid-In Capital [Member] Additional Paid-In Capital [Member] Measurement Frequency Measurement Frequency [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Trading Symbol Trading Symbol Milestone payment Milestone Payment Milestone payment. Adjustments or reconciling items Adjustments or reconciling items. Adjustments or reconciling items Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Fair value on a recurring basis [Member] Fair Value, Recurring [Member] Lessee, Operating Lease, Liability, to be Paid Total lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: interest Less: interest Equity Components Equity Components [Axis] Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Research and development expenses Equity Component Equity Component [Domain] Proceeds From Issuance Of Common Stock Via Employee Stock Purchase Plan Proceeds from issuance of common stock via employee stock purchase plan. Proceeds from issuance of common stock via employee stock purchase plan Asset Class Asset Class [Axis] Investments, Total Investments Investments Summary of Net Assets Acquired Based on Estimated Fair Values Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Address Type [Domain] Business Acquisition Business Combination [Axis] Issuance of common stock via employee stock purchase plan, shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Collaboration Agreements Collaborative Arrangement, Accounting Policy [Policy Text Block] Common Stock, Voting Rights Common Stock, Voting Rights Maximum [Member] Maximum [Member] Impairment of Intangible Assets (Excluding Goodwill) Impairment of Intangible Assets (Excluding Goodwill), Total Impairment of intangible asset Weighted Average Sales Price Per Share Weighted average sales price per share. Commission and other offering expenses. Commissions and other offering expenses Commissions and other offering expenses Entity Addresses, Address Type [Axis] Statistical Measurement Statistical Measurement [Axis] Prepaid expenses Prepaid expenses Prepaid balance Prepaid Expense, Current Common stock, $0.001 par value; 300,000,000 shares authorized as of September 30, 2023, and December 31, 2022; 123,161,066 and 121,112,234 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common stock, $0.001 par value; 300,000,000 shares authorized as of March 31 2026, and December 31, 2025; 189,209,453 and 173,868,949 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Additional Payment Included in Revenue Upon Achievement Of Other Specified Development Commercialization And Sales Based Milestones Does Not Exercise Option To Participate In Collaboration Additional Payment Included in Revenue Upon Achievement Of Other Specified Development Commercialization And Sales Based Milestones Does Not Exercise Option To Participate In Collaboration Additional payment included in revenue upon achievement of other specified development commercialization and sales based milestones does not exercise option to participate in collaboration Change in fair value of Contingent Earnout Payments Business combination contingent consideration liability, contingent earnout payments Business combination contingent consideration liability, contingent earnout payments Business combination contingent consideration liability, contingent earnout payments. Employee Related Expenses Employee related expenses. Employee related expenses Unaudited Interim Financial Information Unaudited Interim Financial Information Policy [Text Block] Unaudited interim financial information. Genentech Agreement [Member] Genentech Agreement [Member] Genentech agreement. Preferred stock shares authorized Preferred Stock, Shares Authorized Total, Unrealized Losses Total, Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Total, Unrealized Losses Collaboration And License Arrangement [Table] Collaboration And License Arrangement [Table] Collaboration and license arrangement. Schedule Of Business Acquisitions By Acquisition [Table] Business Combination [Table] Segment net loss Segment Net Income (Loss) Segment net income (loss). Segment net loss Entity Registrant Name Entity Registrant Name Stock-based compensation expense associated with accelerated vesting for certain stock options Share-Based Payment Arrangement, Accelerated Cost Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Total other income, net Other Non-Operating Income (Expense) Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional paid-in capital Additional Paid in Capital Subsequent Events [Abstract] Measurement Frequency Measurement Frequency [Axis] Proceeds from Issuance of Common Stock Net proceeds Proceeds from issuance of common stock upon exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Compensation Related Costs, Policy [Policy Text Block] Stock Compensation Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive gain (loss) Consolidation Items [Axis] Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment License Agreements License Agreements Disclosure [Text Block] Disclosure of license agreements. Total assets Assets Property, Plant and Equipment [Table] Income Statement [Abstract] Nature Of Business And Basis Of Presentation [Table] Nature Of Business And Basis Of Presentation [Table] Nature of business and basis of presentation. Common stock shares sold Stock Issued During Period, Shares, New Issues Issuance of common stock via at-the-market offerings, net,share Business Combination [Abstract] Net loss per share, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net loss per share, diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Reportable Segment Revenue, Operating Expenses, and Net Loss Operating Segments [Member] Operating Segments [Member] Dividends declared Dividends, Common Stock Dividends, Common Stock, Total Collaboration And License Arrangement [Abstract] Collaboration and license arrangement. City Area Code City Area Code Commitments and Contingencies Disclosure [Line Items] Commitments And Contingencies Disclosure [Line Items] Commitments and contingencies disclosure. Other Comprehensive Income (Loss), Net of Tax Total other comprehensive (loss) income Two thousand twenty one sales agreement. Two Thousand Twenty One Sales Agreement [Member] 2021 Sales Agreement [Member] Loss on initial consolidation of VIE Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Loss On Initial Consolidation Of Variable Interest Entity Business combination recognized identifiable assets acquired and liabilities assumed assets loss on initial consolidation of variable interest entity. Acquired IPR&D asset Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Asset Business combination recognized identifiable assets acquired and liabilities assumed in process research and development asset. Business Acquisition [Line Items] Business Combination [Line Items] Net proceeds Net Proceeds from Issuance of Common Stock Net proceeds from issuance of common stock. Number Of New Programs Number of new programs. Number of new programs Counterparty Name Counterparty Name [Domain] Issuance of common stock via employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term Segment Reporting Information [Line Items] Preferred Stock Dividends and Other Adjustments, Total Deemed dividend resulting from extinguishment upon modification of series C preferred stock Preferred Stock Dividends and Other Adjustments Investments [Abstract] Aggregate fair value consideration transferred Business Combination, Consideration Transferred, Equity Interest Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Loss from operations Operating Income (Loss) Accumulated Deficit [Member] Retained Earnings [Member] Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Offering expenses. Offering Expenses Offering expenses Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock compensation expense Restructuring and Related Cost, Number of Positions Eliminated Number of involuntarily terminated employees Precision Oncology And Genetic Diseases [Member] Precision Oncology And Genetic Diseases [Member] Precision Oncology And Genetic Diseases. Less than 12 Months, Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Non-current operating lease liabilities Operating lease liabilities, net of current portion Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Investments [Member] Investments [Member] Investments, Fair Value Disclosure, Total Total investments Investments, Fair Value Disclosure Operations And Comprehensive Loss Statement [Abstract] Operations and Comprehensive Loss Statement [Abstract]. Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Debt Securities Available For Sale [Table] Debt Securities, Available-for-Sale [Table] Entity Interactive Data Current Entity Interactive Data Current Income Statement Location Statement of Income Location, Balance [Domain] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Net amortization of premiums and discounts on investments Accretion (Amortization) of Discounts and Premiums, Investments Issued shares of common stock Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares Number of new discovery stage programs. Number Of New Discovery Stage Programs Number of discovery stage programs Schedule of Changes in Contingent Consideration Liability Schedule Of Changes In Contingent Consideration Liability [Table Text Block] Schedule of changes in contingent consideration liability. Entity Tax Identification Number Entity Tax Identification Number Revenue: Revenues [Abstract] Interest income Interest Income, Other Interest income Local Phone Number Local Phone Number Related Party Transaction Related Party Transaction [Domain] External Costs for Platform Technologies and Preclinical Programs External costs for platform technologies and preclinical programs. External costs for platform technologies and preclinical programs Other current liabilities Other Liabilities, Current Other Liabilities, Current, Total Genentech [Member] Genentech Inc [Member] Genentech Inc. Accounting Policies [Abstract] Gross Proceeds From Issuance Of Common Stock Gross proceeds from issuance of common stock. Gross proceeds from issuance of common stock Revenue from Contract with Customer, Excluding Assessed Tax, Total Collaboration revenue License and other revenue Revenue from license agreement Lessee, Operating Lease, Liability, to be Paid, Year Four 2029 Class of Stock Class of Stock [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Change in fair value of Contingent Milestone Payments Business combination contingent consideration arrangements change in amount of contingent milestone payments Business combination contingent consideration arrangements change in amount of contingent milestone payments. President and Chief Executive Officer. President and Chief Executive Officer [Member]